Xintela reports positive results from completed horse study
Xintela AB (publ), announces today that the company’s completed horse study met its primary endpoint, demonstrating that Xintela’s stem cells are safe. Xintela can now take the next step in the development of an effective, safe stem cell product for the treatment of cartilage damage and osteoarthritis. “We are very pleased to report a positive […]
Xintela recruits Rickard Mosell as Head of Business Development
On 12 September 2016, Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016. Rickard Mosell will leave his current position as CEO of Ideon Innovation and will be responsible for Xintela’s business development and financing. Rickard Mosell will also be a member of Xintela’s management team. Rickard […]
Xintela receives 1,5 MSEK in dispute settlement
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation. The background to the dispute is that the counter party, who had an assignment from Xintela to validate one of the company’s patents, missed the deadline for validation with the consequence that the patent was not validated in […]
Xintela initiates a study on the treatment of cartilage damage in horses in the USA
Xintela AB (publ) announces today that the company have initiated a study, in the USA, on the treatment of cartilage damage in horses. The study is being conducted in collaboration with an eminent research group at Cornell Univesity. Xintela’s stem cells have been injected into horse joints and the study is expected to be completed […]
